GSK selling off a U.S. site; Sarepta founds a translational R&D lab;

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce

@DamianFierce: Today's the FDA decision deadline for Keytruda's lung cancer app. Can't wait to see the TV ad. | Follow @DamianFierce

> Sarepta Therapeutics ($SRPT) signed a four-year agreement with researchers from Australia's Murdoch University to create the Sarepta Translational Laboratory, devoted to investigating applications for the company's technology beyond Duchenne muscular dystrophy. More

> GlaxoSmithKline ($GSK), in the process of downsizing and consolidating its U.S. operation, has put a 192,000-square-foot Pittsburgh site up for sale. News

> Ongoing bearishness on Wall Street isn't interrupting the steady stream of companies lining up to go public, Reuters reports, including a handful of biotechs. Story

Medical Device News

@FierceMedDev: Illumina expands in China with cancer Dx deal. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Study: Oraya radiation tech reduces need for eye injections in AMD patients. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: U.K. patient group demands government override Roche's Kadcyla patents. Article | Follow @EmilyWFierce

> Google sees independent startups as key to new Alphabet reorganization. Report

> NIH's BRAIN initiative, philanthropic Kavli Foundation provide $185M to study brain science. More

> Siemens nabs Abbott SVP to run healthcare in North America. Article

Pharma News

@FiercePharma: MSF campaigns at UN summit meeting to ease pressure on India's drug IP policies. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: Obstacles aside, Boehringer sees class-topping prospects for Ofev, Spiolto. FiercePharmaMarketing story | Follow @CarlyHFierce

> Novartis targets Amgen's Enbrel with second biosimilar app. Story

> Ackman's fund takes a beating on Valeant pricing worries. Item

> FTC weighs in on Mylan case, saying generics tweaking may be anticompetitive. Article